World Health Organization

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

Retrieved on: 
Tuesday, April 2, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MSD, Breast cancer, Goserelin, Patient, Lung, Social media, Immunoglobulin G, National Cancer Institute, Neoplasm, Merck & Co., TNBC, Capecitabine, DXD, BRCA, Clinical Cancer Research, Metabolism, Immunology, Biopharmaceutical, World Health Organization, Cancer, Safety, ADC, BLA, Daiichi Sankyo, Vinorelbine, IHC, Mutation, NSCLC, Disease, Merck, AKT, Death, MD, AstraZeneca, PARP, Oncotarget, PFS, FDA, OS, HER2, Eribulin, Cleavage, Progression-free survival, Triple-negative breast cancer, Female, Emerging, Olaparib, Biology, Sapporo Medical University, Medicine, Pharmaceutical industry

The safety profile of datopotamab deruxtecan was consistent with that observed in other ongoing trials with no new safety concerns identified.

Key Points: 
  • The safety profile of datopotamab deruxtecan was consistent with that observed in other ongoing trials with no new safety concerns identified.
  • Additional regulatory submissions for datopotamab deruxtecan in lung and breast cancer are underway globally.
  • A comprehensive global clinical development program is underway with more than 20 trials evaluating the efficacy and safety of datopotamab deruxtecan across multiple cancers, including NSCLC, triple-negative breast cancer (TNBC) and HR-positive, HER2-negative breast cancer.
  • Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer.

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 28, 2024
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Diagnosis, De novo, PIN, Obesity, MRI, Syndrome, Metabolism, KCH, Knowledge Organization (journal), International, National Health Service, NHS, Research, Radiology, MASH, Trial of the century, International Classification of Diseases, Hepatology, World Health Organization, Data collection, Prediabetes, NDRA, Liver, Type 2 diabetes, Liver disease, Marketing, NAFLD, Endocrinology, Video game

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update.
  • Highlights from the fourth quarter of 2023 and recent weeks include:
    Installed first TAEUS system in the UK at King’s College Hospital for clinical evaluation.
  • In the third quarter of 2023, ENDRA submitted a De Novo request for its TAEUS liver system to the FDA.
  • In the fourth quarter of 2023, the FDA issued an Additional Information (AI) request to ENDRA.

Synthetic Hormones Market Research Report 2024: Development of New Delivery Systems and Formulations, & Demand for HRT - Global Analysis and Forecast, 2023-2033 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 27, 2024
Pharmaceutical, Health, Other Health, Hospital, Peptide, Birth, Hypothyroidism, Biotechnology, Prevalence, Growth, Human body, Incidence, Insulin, Diabetes, Patient, Conditional sentence, Research, Menopause, World Health Organization, Investment, Skin, Hormone replacement therapy, Safety, HRT, WHO, Region, Administration, Ageing, Pharmaceutical industry

The development of new delivery systems and formulations that enhance patient compliance and reduce side effects further fuels the market growth.

Key Points: 
  • The development of new delivery systems and formulations that enhance patient compliance and reduce side effects further fuels the market growth.
  • Overall, the synthetic hormones market is expected to continue growing, driven by the need for effective treatments for hormonal disorders and the ongoing research and development in this field.
  • The increasing occurrence of hormonal disorders, including hypothyroidism, diabetes, and imbalances, plays a crucial role in propelling the synthetic hormones market.
  • The hospital pharmacies segment accounted for the largest share of the global synthetic hormones market (by end user) in 2022.

FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)

Retrieved on: 
Tuesday, March 26, 2024
Cardiology, Biotechnology, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Other Health, MSD, FC, Exercise, Breakthrough therapy, Blood, Risk, Patient, Orthostatic hypertension, MRK, World Health Organization, Heart, WHO, Multimedia, PAH, Food, Pharmaceutical industry

“The Pulmonary Hypertension Association welcomes the development of new therapies for those with PAH,” said Matt Granato, president and chief executive officer, Pulmonary Hypertension Association.

Key Points: 
  • “The Pulmonary Hypertension Association welcomes the development of new therapies for those with PAH,” said Matt Granato, president and chief executive officer, Pulmonary Hypertension Association.
  • In the WINREVAIR treatment group, the placebo-adjusted median increase in 6MWD was 41 meters (95% CI: 28, 54; p
  • The median treatment difference in PVR between WINREVAIR and placebo was -235 dynes*sec/cm5 (95% CI: -288, -181; p
  • The median treatment difference in NT-proBNP between WINREVAIR and placebo was -442 pg/mL (95% CI: -574, -310; p

Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes

Retrieved on: 
Tuesday, March 26, 2024
Other Philanthropy, Biotechnology, Pharmaceutical, Managed Care, Oncology, Health, Philanthropy, Clinical Trials, Well, Diagnosis, BMY, World Health Organization, Patients Association, Less, Organization, Social, Education, Bone marrow, Survival, Health equity, Social support, Genetics, Patient, Good Health, Corporate Affairs, Pancreatic cancer, Cancer, Anti-transglutaminase antibodies, Bristol Myers Squibb, Blood Cancer UK, United, Telephone numbers in Hungary, Sistema, Oral cancer, Clinical trial, WHO, Multimedia, Hepatocellular carcinoma, Nursing

Bristol Myers Squibb (NYSE: BMY) today unveiled a $1.8 million initiative to advance health equity by addressing social determinants of health (SDoH) in four countries with underserved patient needs, including Brazil, India, Thailand, and the United Kingdom.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today unveiled a $1.8 million initiative to advance health equity by addressing social determinants of health (SDoH) in four countries with underserved patient needs, including Brazil, India, Thailand, and the United Kingdom.
  • The new health equity grants are an extension of the company’s broader long-term commitment to invest $150M in health equity by 2025 .
  • At Bristol Myers Squibb, health equity is the opportunity for all people and communities across the globe to attain their full potential for health and well-being.
  • Our work extends beyond traditional healthcare boundaries, emphasizing the importance of community voices and cross-sector partnerships in co-creating solutions that drive meaningful and equitable health outcomes worldwide.

Yes! We Can End TB & AIDS, Says AHF

Retrieved on: 
Friday, March 22, 2024
White House, Federal Government, Public Policy, Other Health, General Health, Women, Philanthropy, Advocacy Group Opinion, Infectious Diseases, Government, Men, LGBTQ+, Foundation, Other Philanthropy, AIDS, Consumer, Health, Coinfection, AIDS Healthcare Foundation, Tuberculosis, World Tuberculosis Day, HIV, Global health, Education, Death, Infection, World Health Organization, Multidrug-resistant tuberculosis, TB, MDR-TB, AHF, Multimedia, Pharmaceutical industry

We Can End TB & AIDS’ commemorations to honor the millions of lives lost to TB while urging leaders at all levels of government to prioritize TB prevention, testing, and treatment efforts.

Key Points: 
  • We Can End TB & AIDS’ commemorations to honor the millions of lives lost to TB while urging leaders at all levels of government to prioritize TB prevention, testing, and treatment efforts.
  • View the full release here: https://www.businesswire.com/news/home/20240322482439/en/
    AIDS Healthcare Foundation (AHF) country teams, which have prioritized screening for TB in clinics—along with preventing and treating HIV/TB co-infection—will hold World TB Day commemorations around the globe.
  • Integrating TB prevention and care into HIV programs, which AHF has done, is essential for comprehensive healthcare.
  • We Can End TB & AIDS.’”
    According to the World Health Organization, TB claimed 1.3 million lives in 2022, including 167,000 people living with HIV, with an estimated nearly 11 million people falling ill to TB worldwide.

Combatting Tuberculosis in the Workplace: International SOS Shares Key Actions for Businesses

Retrieved on: 
Friday, March 22, 2024
Other Health, Human Resources, Consulting, Small Business, Other Travel, Practice Management, Education, Training, Managed Care, Professional Services, Travel, Other Transport, Hospitals, Transport, Health, Diagnosis, International SOS, Disease, Risk, International, Internal, Risk assessment, World Health Organization, Safety, WHO, TB

In the lead-up to World Tuberculosis (TB) Day on 24 March, International SOS , the world's leading health and security risk services company, highlights the importance of safeguarding employees from TB.

Key Points: 
  • In the lead-up to World Tuberculosis (TB) Day on 24 March, International SOS , the world's leading health and security risk services company, highlights the importance of safeguarding employees from TB.
  • While TB occurs worldwide, South-East Asia experiences the highest burden.2 International SOS data further highlights this, reporting a consistent trend over the past four years of TB-related cases in Asia, particularly in Indonesia and Vietnam.
  • International SOS offers the following key actions organisations can take to help end the TB epidemic:
    Awareness campaign: Raise awareness and educate employees about TB symptoms, transmission and prevention measures.
  • Risk assessment: Organisations should perform a risk assessment for employees working with individuals at an increased risk of TB infection.

COVID-19 Monthly Newsletter Service - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Publishing, Health, FDA, COVID-19, Communications, Clinical Trials, MHLW, CSL, Abivax, AstraZeneca, Partnership, University, Ageing, EUL, Arcturus Therapeutics, UNICEF, Bharat Biotech, Ministry of Health, XBB, Messenger, Laboratory, World Health Organization, OTC, Therapy, Johnson & Johnson, Vaccination, Rapid antigen test, Phase II, WHO, CSL Limited, Ministry, Vaccine, Marketing, Fulcrum, UN, Pharmaceutical industry

The "COVID-19 Monthly Snapshot" newsletter has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "COVID-19 Monthly Snapshot" newsletter has been added to ResearchAndMarkets.com's offering.
  • In November 2023, 64 investigational drugs were active in Phase 3 of clinical development.
  • Globally, the overall confirmed cases of COVID-19 reached more than 772 million as of November 22, 2023.
  • Fifty-eight COVID-19 vaccines were evaluated in Phase 3, 40 in Phase 2, 84 in Phase 1, and 199 in pre-clinical stages.

Global Guidewires (Nitinol, Stainless Steel, Others) Market Report 2024: Analysis & Forecasts 2019-2022 and 2023-2029 - Minimally Invasive Techniques Expand, Boosting Guidewire Utilization - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 12, 2024
General Health, Health, Medical Supplies, Medical Devices, Disease, PVI, Friction, ERCP, Coronary artery disease, Conditional sentence, Bacteria, Epidemiology, Specialization, Risk, Investment, Infection, Patient safety, USD, Surgery, Non-communicable disease, Cardiovascular disease, Fungal infection, Obesity, Biotechnology, Peripheral artery disease, Porter's five forces analysis, Diabetes, Chlorhexidine, World Health Organization, Safety, Fatigue, Hypertension, Cardiology, Neurology, Urology, Prevalence, Death, PCI, Diagnosis, Arrhythmia, Temperature, Growth, Incidence, Anatomy, SWOT, Mortality, Stainless steel, WHO, Nickel titanium, Physician, Medical imaging

Guidewires Market is being propelled increasing prevalence of cardiovascular diseases, technological advancements in guidewire design and materials, rising demand for minimally invasive procedures, and expanding healthcare infrastructure in developing economies.

Key Points: 
  • Guidewires Market is being propelled increasing prevalence of cardiovascular diseases, technological advancements in guidewire design and materials, rising demand for minimally invasive procedures, and expanding healthcare infrastructure in developing economies.
  • As the prevalence of risk factors such as obesity, diabetes, and hypertension increase, so does the incidence of cardiovascular diseases.
  • Guidewires are essential tools in percutaneous coronary interventions (PCI), peripheral vascular interventions (PVI), and electrophysiology procedures, driving the demand for guidewires.
  • The increasing prevalence of chronic diseases worldwide drives the demand for guidewires by necessitating minimally invasive interventions for diagnosis and treatment.

Walking 5,000 Steps Three Times Per Week Could Add Three Years to Life Expectancy

Retrieved on: 
Tuesday, March 12, 2024
Technology, Diabetes, Fitness & Nutrition, Other Technology, Software, Other Health, General Health, Health, Data Management, Artificial Intelligence, World Health Organization, Exercise, Vitality, Science, Risk, Ageing, Public, Mental health, Research, Policy, Mortality, Social isolation, Cancer, Death, Life expectancy, Woman, Behavior, Habit, Notifiable disease, Management

“Healthy habits can profoundly extend the quality and length of life,” said Adrian Gore, Founder of Discovery Vitality.

Key Points: 
  • “Healthy habits can profoundly extend the quality and length of life,” said Adrian Gore, Founder of Discovery Vitality.
  • People aged 65 and older saw a 52% reduction in their mortality risk after sustaining a habit of 7,500 steps three or more times per week.
  • People who sustain a habit of 10,000 steps three times a week for three years can reduce their type 2 diabetes risk by up to 41%.
  • Increasing the frequency of exercise to four or more times a week saw a 57% reduction in the risk of developing type 2 diabetes.